EWTX (Edgewise Therapeutics) Institutional Ownership: 116.09% (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $41.94
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics Institutional Ownership?

Edgewise Therapeutics EWTX -0.10% 28 Institutional Ownership is 116.09% as of Sep. 04, 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Edgewise Therapeutics's institutional ownership is 116.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Edgewise Therapeutics's Insider Ownership is 0.27%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Edgewise Therapeutics's Float Percentage Of Total Shares Outstanding is 70.97%.

Edgewise Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Edgewise Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics Institutional Ownership Chart

Edgewise Therapeutics Historical Data

The historical data trend for Edgewise Therapeutics can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 31.42 32.11 33.07 33.71 34.15 36.28 37.18 40.99 41.95 42.15
EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 116.09% mean?
Edgewise Therapeutics (EWTX) has a Institutional Ownership of 116.09% as of Sep. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Edgewise Therapeutics and its competitors.
Is Edgewise Therapeutics' Institutional Ownership too high?
Edgewise Therapeutics' current Institutional Ownership is 116.09%. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' Institutional Ownership compare to DYN and PBLS?
Edgewise Therapeutics' Institutional Ownership of 116.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Edgewise Therapeutics and its competitors. Edgewise Therapeutics's current Institutional Ownership is 116.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current Institutional Ownership of 116.09%. The current Institutional Ownership is 116.09%. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current Institutional Ownership is 116.09% as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.94
Price